Engesæter, Birgit <br/><br/>
Dacarbazine and the agonistic TRAIL receptor-2 antibody lexatumumab induce synergistic anticancer effects in melanoma.  [electronic resource] 

 -  PloS one  2012 
 - e45492 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1932-6203 
<br/><br/><label>Standard No.: </label>10.1371/journal.pone.0045492  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized<br/>Antineoplastic Agents--administration & dosage<br/>Apoptosis--drug effects<br/>Caspases--metabolism<br/>Cell Death--drug effects<br/>Cell Line, Tumor<br/>Cell Survival--drug effects<br/>Dacarbazine--administration & dosage<br/>Drug Synergism<br/>Female<br/>Humans<br/>Inhibitor of Apoptosis Proteins--metabolism<br/>Melanoma--metabolism<br/>Mice<br/>Proto-Oncogene Proteins c-bcl-2--metabolism<br/>Receptors, TNF-Related Apoptosis-Inducing Ligand--agonists<br/>Tumor Stem Cell Assay<br/>Xenograft Model Antitumor Assays